NO843049L - Fremgangsmaate til isolering og rensing av interferon - Google Patents
Fremgangsmaate til isolering og rensing av interferonInfo
- Publication number
- NO843049L NO843049L NO843049A NO843049A NO843049L NO 843049 L NO843049 L NO 843049L NO 843049 A NO843049 A NO 843049A NO 843049 A NO843049 A NO 843049A NO 843049 L NO843049 L NO 843049L
- Authority
- NO
- Norway
- Prior art keywords
- parts
- volume
- interferon
- ethylene glycol
- methanol
- Prior art date
Links
- 108010050904 Interferons Proteins 0.000 title claims description 41
- 102000014150 Interferons Human genes 0.000 title claims description 40
- 229940079322 interferon Drugs 0.000 title claims description 32
- 238000000034 method Methods 0.000 title claims description 22
- 238000004140 cleaning Methods 0.000 title description 2
- 238000009413 insulation Methods 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 239000000741 silica gel Substances 0.000 claims description 14
- 229910002027 silica gel Inorganic materials 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 6
- -1 aliphatic halohydrocarbon Chemical class 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 5
- 239000005695 Ammonium acetate Substances 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 235000019257 ammonium acetate Nutrition 0.000 claims description 5
- 229940043376 ammonium acetate Drugs 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 238000011097 chromatography purification Methods 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 238000013375 chromatographic separation Methods 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 229940047124 interferons Drugs 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 150000003510 tertiary aliphatic amines Chemical class 0.000 description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- AOQKTXNIXJZEJT-UHFFFAOYSA-N formic acid;methanol;hydrate Chemical compound O.OC.OC=O AOQKTXNIXJZEJT-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833327710 DE3327710A1 (de) | 1983-07-29 | 1983-07-29 | Verfahren zur isolierung und reinigung von interferon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO843049L true NO843049L (no) | 1985-01-30 |
Family
ID=6205464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO843049A NO843049L (no) | 1983-07-29 | 1984-07-27 | Fremgangsmaate til isolering og rensing av interferon |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0133284A2 (fi) |
| JP (1) | JPS6069099A (fi) |
| KR (1) | KR850001289A (fi) |
| AU (1) | AU3127384A (fi) |
| DE (1) | DE3327710A1 (fi) |
| DK (1) | DK369084A (fi) |
| ES (1) | ES534686A0 (fi) |
| FI (1) | FI842982A (fi) |
| GR (1) | GR82439B (fi) |
| HU (1) | HUT35003A (fi) |
| IL (1) | IL72511A0 (fi) |
| NO (1) | NO843049L (fi) |
| PT (1) | PT78981A (fi) |
| ZA (1) | ZA845818B (fi) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3500681A1 (de) * | 1985-01-11 | 1986-07-17 | Hoechst Ag, 6230 Frankfurt | Verfahren zur isolierung und reinigung von lymphokinen |
| US4675387A (en) * | 1985-07-26 | 1987-06-23 | E. I. Du Pont De Nemours And Company | Method for extracting protein with organic acid |
-
1983
- 1983-07-29 DE DE19833327710 patent/DE3327710A1/de not_active Withdrawn
-
1984
- 1984-07-23 HU HU842840A patent/HUT35003A/hu unknown
- 1984-07-25 EP EP84108768A patent/EP0133284A2/de not_active Withdrawn
- 1984-07-26 IL IL72511A patent/IL72511A0/xx unknown
- 1984-07-26 PT PT78981A patent/PT78981A/pt unknown
- 1984-07-26 FI FI842982A patent/FI842982A/fi not_active Application Discontinuation
- 1984-07-27 GR GR75439A patent/GR82439B/el unknown
- 1984-07-27 AU AU31273/84A patent/AU3127384A/en not_active Abandoned
- 1984-07-27 DK DK369084A patent/DK369084A/da not_active Application Discontinuation
- 1984-07-27 JP JP59155696A patent/JPS6069099A/ja active Pending
- 1984-07-27 ES ES534686A patent/ES534686A0/es active Granted
- 1984-07-27 NO NO843049A patent/NO843049L/no unknown
- 1984-07-27 ZA ZA845818A patent/ZA845818B/xx unknown
- 1984-07-28 KR KR1019840004497A patent/KR850001289A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES8503955A1 (es) | 1985-04-01 |
| EP0133284A2 (de) | 1985-02-20 |
| HUT35003A (en) | 1985-05-28 |
| AU3127384A (en) | 1985-01-31 |
| DK369084A (da) | 1985-01-30 |
| GR82439B (fi) | 1984-12-13 |
| ES534686A0 (es) | 1985-04-01 |
| DE3327710A1 (de) | 1985-02-07 |
| KR850001289A (ko) | 1985-03-18 |
| JPS6069099A (ja) | 1985-04-19 |
| ZA845818B (en) | 1985-03-27 |
| FI842982A (fi) | 1985-01-30 |
| IL72511A0 (en) | 1984-11-30 |
| PT78981A (de) | 1984-08-01 |
| DK369084D0 (da) | 1984-07-27 |
| FI842982A0 (fi) | 1984-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6471500B1 (en) | Process for producing erythropoietin containing no animal proteins | |
| Fujiki et al. | Identification of a mutation within the structural gene for the a subunit of DNA-dependent RNA polymerase of E. coli | |
| Webber et al. | A fifth chloroplast-encoded polypeptide is present in the photosystem II reaction centre complex | |
| JPS61172899A (ja) | ペプチド及びその製造方法 | |
| NO830697L (no) | Homogent menneske-immun-interferon og fremstilling derav | |
| JP2756279B2 (ja) | ヒルジンの単離および精製法 | |
| CA1186303A (en) | Polypeptide compositions | |
| KR910006603B1 (ko) | 인체 γ-인터페론 단량체의 제조방법 | |
| Okamoto et al. | Purification and molecular cloning of a butyrolactone autoregulator receptor from Streptomyces virginiae. | |
| Francesconi et al. | Purification and characterization of OBF1: a Saccharomyces cerevisiae protein that binds to autonomously replicating sequences | |
| NO843049L (no) | Fremgangsmaate til isolering og rensing av interferon | |
| US4617378A (en) | Purification of biologically active human immune interferon | |
| Lanzendörfer et al. | Structure and function of the DNA-dependent RNA polymerase of Sulfolobus | |
| Reddi | Structural differences in the nucleic acids of some tobacco mosaic virus strains: II. Di-and tri-nucleotides in ribonuclease digests | |
| Yaron et al. | Synthesis and immunological properties of the oligolysyl-Niε-dinitrophenyllysine and oligolysylalanylalanylalanyl-Niε-dinitrophenyllysine peptide series | |
| Mosser et al. | Proteins of Rous-associated virus type 61: polypeptide stoichiometry and evidence that glycoprotein gp35 is not a cleavage product of gp85 | |
| EP0244147A2 (en) | Purification process for hybrid proteins | |
| EP0071647B1 (en) | Process for recovering interferon | |
| US4681931A (en) | Process for the isolation and purification of alpha-interferons | |
| Robins et al. | Nucleoside peptides. I. Synthesis of 5'-deoxy-5'amino-5'-N-aminoacyl peptide derivatives of guanosine, adenosine, and 2'-deoxyadenosine and their effect of cell-free protein synthesis | |
| JPS62500380A (ja) | 抗ウィルスペプチド類 | |
| McCorquodale et al. | Gene D5 product of bacteriophage T5: DNA-binding protein affecting DNA replication and late gene expression | |
| EP0114527B1 (en) | Carrier sheets of paper and nitrocellulose bearing polyuridylic acid and polythymidylic acid residues and their use in the preparative recovery of mrna | |
| Shoji et al. | Simple and rapid identification of phosphorylated peptides from bovine brain myelin basic protein by reversed-phase high-performance liquid chromatography | |
| Wu et al. | Identification, expression, and characterization of the pseudorabies virus DNA-binding protein gene and gene product |